Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 29, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Third-Generation Nanopore Sequencing for Post-Transplant Chimerism Monitoring.

Pascal Pedini1,2, Emma Rateau1, Sandrine Maioli1

  • 1Immunogenetics Laboratory, Reference Laboratory for the Study of Chimerism, Établissement Français du Sang PACA-Corse, Marseille, France.

HLA
|May 28, 2026
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Characterisation of the Novel HLA-DRB3*01:01:27 Allele Using Third-Generation Sequencing Methods.

HLA·2026
Same author

Characterisation of the Novel HLA-DQA1*01:02:32 Allele Using Third-Generation Sequencing Methods.

HLA·2026
Same author

Cryptosporidiosis in Ptients with Inborn Errors of Immunity: Retrospective cohort study of the French National Reference Center (CEREDIH).

The Journal of infectious diseases·2026
Same author

Nationwide Centralized Manufacturing and Fresh Distribution of TCRαβ/CD19-DepletedGrafts: A Real-World French Experience.

Transplantation and cellular therapy·2026
Same author

Characterisation of the Novel HLA-C*12:459 Allele Using Third-Generation Sequencing Methods.

HLA·2026
Same author

Immunotherapy as rescue for cardiomyopathy in Omenn syndrome.

Journal of human immunity·2026
Same journal

The Novel Allele, HLA-C*14:167, With a Non-Synonymous Mutation in Exon 1.

HLA·2026
Same journal

Impact of Excluding Anti-HLA-C and -DP Antibodies From the Allocation System on Kidney Transplant Access.

HLA·2026
Same journal

Resolution-Aware Eight-Locus HLA Diversity Profiling and Rare Allele Interpretation in an Eastern Chinese Transplant-Typing Cohort.

HLA·2026
Same journal

Value of Genetically Rare Cord Blood Units Beyond Conventional Quality Metrics.

HLA·2026
Same journal

Characterisation of the Novel HLA-B*07:05:15 Allele by Sequencing-Based Typing.

HLA·2026
See all related articles

Third-generation sequencing (TGS) offers a rapid and flexible approach for post-transplant chimerism monitoring. The ONtrack assay demonstrates excellent analytical performance, providing actionable insights for hematopoietic stem cell transplantation follow-up.

Area of Science:

  • Molecular diagnostics and personalized medicine
  • Hematopoietic stem cell transplantation (HSCT) monitoring

Background:

  • Post-transplant chimerism monitoring is crucial for HSCT success, assessing engraftment, rejection, and relapse.
  • Current methods like qPCR, dPCR, and NGS have limitations in turnaround time and workflow flexibility for urgent clinical needs.

Purpose of the Study:

  • To evaluate ONtrack, the first commercial third-generation sequencing (TGS) assay for post-transplant chimerism quantification.
  • To assess the analytical performance and operational flexibility of TGS compared to established methods.

Main Methods:

  • Analysis of 30 diverse samples (controls and clinical specimens) using the ONtrack TGS assay.
  • Comparison of ONtrack results with quantitative PCR (qPCR), digital PCR (dPCR), and next-generation sequencing (NGS).
Keywords:
NGSTGSchimerismdigital PCRqPCR

More Related Videos

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

Sequencing of mRNA from Whole Blood using Nanopore Sequencing
11:26

Sequencing of mRNA from Whole Blood using Nanopore Sequencing

Published on: June 3, 2019

Related Experiment Videos

Last Updated: May 29, 2026

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
10:41

An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues

Published on: April 5, 2018

Sequencing of mRNA from Whole Blood using Nanopore Sequencing
11:26

Sequencing of mRNA from Whole Blood using Nanopore Sequencing

Published on: June 3, 2019

  • Evaluation of analytical performance using correlation coefficients, Bland-Altman, and Z-score analyses.

    • Main Results:

    • ONtrack demonstrated excellent analytical performance with strong correlations to qPCR (R²=0.955), dPCR (R²=0.990), and NGS (R²=0.998).
    • Reliable detection of mixed chimerism down to 0.5% with good agreement across methods.
    • Complete workflow in approximately 3 hours for a single sample, offering automated data processing and quality controls.

    Conclusions:

    • Third-generation sequencing (TGS) via the ONtrack assay is a valuable, flexible, and rapid complementary solution for post-transplant chimerism monitoring.
    • Its operational versatility supports urgent single-sample testing and batch analyses, particularly beneficial for decentralized laboratories.
    • While marker limitations exist for ultra-low microchimerism, TGS enhances early post-transplant surveillance.